Arbutus has moved into Part 3 of this clinical trial which evaluates repeat dosing of AB-101 for 28 days in patients with cHBV and expects to report preliminary data in the first half of next year.

The acquisition was part of BioNTech's broader oncology strategy, backed by the financial success of its Covid-19 vaccine ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

November 13th has seen a myriad of significant events throughout history, impacting various spheres such as politics, science ...

Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Pfizer (PFE) is exploring the sale of its hospital drugs unit, now called Pfizer Hospital, which was formed after Pfizer bought Hospira for ...

Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...